Welcure Drugs & Pharmaceuticals Ltd Financials
Company Logo

Welcure Drugs & Pharmaceuticals Ltd Financial Statement

Welcure Drugs & Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue299.91
Operating Expense268.77
Net Profit23.30
Net Profit Margin7.77
Earning Per Share2.07
EBIDTA31.14
Effective Tax Rate25.18

Welcure Drugs & Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual24.55
Operating Expenses Annual23.67
Operating Profit Annual2.79
Interest AnnualTBA
Depreciation0.01
Net Profit Annual2.17
Tax Annual0.61

Welcure Drugs & Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning0.02
Cash Flow from Operations-222.03
Cash Flow from Investing-0.06
Cash Flow from Financing222.20
Cash Flow at the End0.13

Welcure Drugs & Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)11.73
PBIT Margin (%)11.69
PBT Margin (%)-118.21
Net PROFIT Margin (%)8.84
Return On Networth / Equity (%)3.81
Return On Networth /Employed (%)2.42
Return On Assets (%)1.94
Total Debt / Equity (X)1.19
Asset Turnover Ratio (%)0.22

Welcure Drugs & Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual0.03
Total Current Assets Annual182.14
Non Current Assets Annual84.84
Total Shareholders Funds Annual102.51
Total Assets Annual266.98

Welcure Drugs & Pharmaceuticals Ltd Earning Calls

No Data Availabe

FAQS on Welcure Drugs & Pharmaceuticals Ltd Financials

As of Sep 24, 2025, Welcure Drugs & Pharmaceuticals Ltd has a market capitalization of 102.27 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Welcure Drugs & Pharmaceuticals Ltd is not with a debt-to-equity ratio of 1.20.

In FY 2024 , Welcure Drugs & Pharmaceuticals Ltd recorded a total revenue of approximately 24.55 Cr marking a significant milestone in the company's financial performance.

Welcure Drugs & Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 1.5% and Infinity% annually, respectively..

Welcure Drugs & Pharmaceuticals Ltd's current PE ratio is 47.13.

Welcure Drugs & Pharmaceuticals Ltd's ROCE averaged -1.7% from the FY ending March 2023 to 2025, with a median of 1.2%. It peaked at 6.7% in March 2023, reflecting strong capital efficiency over the period..

Welcure Drugs & Pharmaceuticals Ltd's latest EBIT is Rs. 2.78 Cr, surpassing the average EBIT of Rs. 0.90 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions